Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2024 Aug 27:15:1446937.
doi: 10.3389/fimmu.2024.1446937. eCollection 2024.

Exploring potential roles of long non-coding RNAs in cancer immunotherapy: a comprehensive review

Asghar Arshi #  1 , Esmaeil Mahmoudi #  2 , Farzaneh Raeisi  1 , Masoud Dehghan Tezerjani  3 , Elham Bahramian  4 , Yeasin Ahmed  4 , Chun Peng  1
Affiliations
Review

Exploring potential roles of long non-coding RNAs in cancer immunotherapy: a comprehensive review

Asghar Arshi et al. Front Immunol. .

Abstract

Cancer treatment has long been fraught with challenges, including drug resistance, metastasis, and recurrence, making it one of the most difficult diseases to treat effectively. Traditional therapeutic approaches often fall short due to their inability to target cancer stem cells and the complex genetic and epigenetic landscape of tumors. In recent years, cancer immunotherapy has revolutionized the field, offering new hope and viable alternatives to conventional treatments. A particularly promising area of research focuses on non-coding RNAs (ncRNAs), especially long non-coding RNAs (lncRNAs), and their role in cancer resistance and the modulation of signaling pathways. To address these challenges, we performed a comprehensive review of recent studies on lncRNAs and their impact on cancer immunotherapy. Our review highlights the crucial roles that lncRNAs play in affecting both innate and adaptive immunity, thereby influencing the outcomes of cancer treatments. Key observations from our review indicate that lncRNAs can modify the tumor immune microenvironment, enhance immune cell infiltration, and regulate cytokine production, all of which contribute to tumor growth and resistance to therapies. These insights suggest that lncRNAs could serve as potential targets for precision medicine, opening up new avenues for developing more effective cancer immunotherapies. By compiling recent research on lncRNAs across various cancers, this review aims to shed light on their mechanisms within the tumor immune microenvironment.

Keywords: cancer biomarkers; cancer immunotherapy; immune response; lncRNA; therapeutic target.

PubMed Disclaimer

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Figures

Figure 1
Figure 1
Production of monoclonal antibodies: step-by-step process involved in the production of monoclonal antibodies (this image was created with BioRender).
Figure 2
Figure 2
Antitumor and protumor activity of B-cells in the cancer tumor microenvironment: B cells can differentiate into plasma cells, which produce antibodies that target neoantigen-expressing tumors, leading to tumor cell death through the complement system, NK cells, and phagocytosis, thus exhibiting antitumor activity. Conversely, B cells can differentiate into regulatory B cells (Bregs, CD19+, CD24+, CD38+), which secrete IL-10, IL-35, and TGF-β, promoting CD4+ T-cell proliferation and upregulating PD-1/PD-L1, ultimately inhibiting antitumor activity. Additionally, plasma cells can contribute to protumor activity by producing antibodies that form circulating immune complexes, leading to inflammation (this image was created with BioRender).
See this image and copyright information in PMC

Similar articles

See all similar articles

References

    1. Flavahan WA, Gaskell E, Bernstein BE. Epigenetic plasticity and the hallmarks of cancer. Science. (2017) 357:eaal2380. doi: 10.1126/science.aal2380 - DOI - PMC - PubMed
    1. Fitzmaurice C, Allen C, Barber RM, Barregard L, Bhutta ZA, Brenner H, et al. . Global, regional, and national cancer incidence, mortality, years of life lost, years lived with disability, and disability-adjusted life-years for 32 cancer groups, 1990 to 2015: A systematic analysis for the global burden of disease study. JAMA Oncol. (2017) 3:524–48. doi: 10.1001/jamaoncol.2016.5688 - DOI - PMC - PubMed
    1. Hernández Borrero LJ, El-Deiry WS. Tumor suppressor p53: Biology, signaling pathways, and therapeutic targeting. Biochim Biophys Acta Rev Cancer. (2021) 1876:188556. doi: 10.1016/j.bbcan.2021.188556 - DOI - PMC - PubMed
    1. Matthews HK, Bertoli C, de Bruin RAM. Cell cycle control in cancer. Nat Rev Mol Cell Biol. (2022) 23:74–88. doi: 10.1038/s41580-021-00404-3 - DOI - PubMed
    1. Goding Sauer A, Siegel RL, Jemal A, Fedewa SA. Current prevalence of major cancer risk factors and screening test use in the United States: disparities by education and race/ethnicity. Cancer Epidemiol Biomarkers Prev. (2019) 28:629–42. doi: 10.1158/1055-9965.Epi-18-1169 - DOI - PubMed

Substances

Grants and funding

The author(s) declare financial support was received for the research, authorship, and/or publication of this article. The work was funded in part by the Cancer Research Society and York University Research Chair Program to CP.

LinkOut - more resources